19 June 2018
Diabetic foot disease (DFD) is globally recognised as the leading cause of all lower-limb amputations, and in Australia alone, it results in 4,400 amputations, 27,600 hospitalisations and nearly 1,700 deaths each year.
07 June 2018
CCRM Australia and Therapeutic Innovation Australia collaborate to develop an information system for regenerative medicine
The Centre for Commercialization of Regenerative Medicine Australia (CCRM Australia) is proud to partner with Therapeutic Innovation Australia (TIA) to jointly develop an information system to curate data on the Australian regenerative medicine sector and to serve as both CCRM Australia’s customer relationship management and project management platforms.
31 May 2018
Novel solutions for biofilm infections are the focus of a collaborative research agreement between the University of Sydney, Whiteley Corporation and the Innovative Manufacturing Cooperative Research Centre (IMCRC).
29 May 2018
Proteomics International signs deal with PrismHealthDx to launch PromarkerD predictive test for diabetic kidney disease in USA
Medical technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) has signed the first licence agreement for its world-leading PromarkerD predictive test for diabetic kidney disease in the United States, creating a partnership with US-based precision medicine and diagnostic services laboratory PrismHealthDx, Inc. (PHDx).
16 May 2018
MTPConnect – the Australian Government’s Medical Technology, Biotechnology, and Pharmaceutical (MTP) Industry Growth Centre – is excited to support the launch of a new Australian initiative ‘ Clinical Trials: Impact & Quality’ (CT:IQ), an inclusive collaboration to ensure the effective and efficient promotion of clinical trials in Australia.
15 May 2018
MTPConnect welcomes the national launch of the Industry Mentoring Network in STEM (IMNIS) program, in conjunction with Industry Growth Centres NERA and METSIgnited. IMNIS has evolved from a small pilot program into a prestigious mentoring initiative involving more than 400 people.
11 May 2018
Three outstanding female leaders have been presented with the 2018 BioMelbourne Network Women in Leadership Awards, celebrating and recognising women at the different stage of their careers who have made outstanding contributions to advancing the biotechnology, medical technology and pharmaceutical sector.
10 May 2018
Find out more about specific initiatives announced in Budget 2018, with a targeted focus on economic growth to drive ongoing innovation, research translation, industry-research collaboration and commercialisation in the Australian MTP sector.
09 May 2018
MTPConnect has welcomed the Australian Government’s 2018 Budget, with a targeted focus on economic growth to drive ongoing innovation, research translation, industry-research collaboration and commercialisation in the Australian MTP sector.
07 May 2018
MTPConnect is delighted to announce that it has appointed Dr Dan Grant as Chief Executive Officer. Dr Grant will commence the role in July 2018, bringing a wealth of experience to MTPConnect and the Australian MTP sector, from an extensive career in the pharmaceutical, medical research and higher education sectors.
30 April 2018
A new professional development program on the commercialisation of medical technology opens applications today with the launch of QUT’s The BridgeTech Program, supported by MTPConnect.
26 April 2018
MTPConnect invites the Australian medical technology sector to join the Australian delegation to The MedTech Conference—September 23 – 26, 2018 in Philadelphia, Pennsylvania—to showcase outstanding innovative medical technologies, Australia's unique capabilities, and build invaluable inroads into international markets.
19 April 2018
Compounds Australia at Griffith University announced today that it has finalised the purchase of the state-of-the-art Hamilton Verso M3 automated compound storage system, part of the Hit ID Platform supported by the MTPConnect Project Fund Program.
17 April 2018
MTPConnect and the Minister for Health, the Hon Greg Hunt MP, today announced the first 11 recipients of $10 million investment from the Australian Government’s $35 million BioMedTech Horizons program. The program aims to help Australia move more cutting-edge ideas and breakthrough discoveries towards proof-of-concept and commercialisation.
16 April 2018
ANDHealth is now accepting applications for the ANDHealth+ (ANDHealth Plus) 2018 Program from mid-stage digital health companies looking to strengthen their clinical and commercial business case in advance of raising venture capital and/ or entering international markets.